AUDENTES THERAPEUTICS, INC. (NASDAQ:BOLD) Files An 8-K Submission of Matters to a Vote of Security HoldersItem 5.07.
Submission of Matters to a Vote of Security Holders.
AUDENTES THERAPEUTICS, INC. (NASDAQ:BOLD) Files An 8-K Submission of Matters to a Vote of Security Holders
On June 8, 2018, Audentes Therapeutics, Inc. (the “Company”) held its 2018 Annual Meeting of Stockholders and the following proposals were adopted:
|
1. |
Election of two Class II directors, Louis Lange and Kush Parmar, each to serve three-year terms through the third annual meeting of stockholders following the 2018 annual meeting and until a successor has been elected and qualified or until earlier resignation or removal: |
|
Nominees |
Shares For |
SharesWithheld |
Broker Non-Votes |
|
Louis Lange |
27,350,557 |
5,750,597 |
1,722,219 |
|
Kush Parmar |
28,208,995 |
4,892,159 |
1,722,219 |
|
2. |
Ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December31, 2018: |
|
Shares For |
SharesAgainst |
Shares Abstaining |
|
34,758,553 |
1,515 |
63,305 |
About AUDENTES THERAPEUTICS, INC. (NASDAQ:BOLD)
Audentes Therapeutics, Inc. is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT). The Company’s subsidiary is Audentes Therapeutics UK Ltd. As of September 30, 2016, the Company had not generated any revenues.
